-+ 0.00%
-+ 0.00%
-+ 0.00%

CK Life Sciences publishes 2025 annual report

PUBT·04/17/2026 08:40:18
Listen to the news
CK Life Sciences publishes 2025 annual report
  • CK Life Sciences annual report for year ended Dec. 31, 2025 outlined a corporate reorganization to intensify pharmaceuticals and diagnostics R&D.
  • TransCode Therapeutics acquired late-stage melanoma vaccine seviprotimut-L in Oct. 2025; CK Life Sciences invested USD 25 million in TransCode to support continued development.
  • Dogwood Therapeutics advanced non-opioid pain candidate Halneuron in Phase 2b for chemotherapy-induced neuropathic pain; interim analysis showed higher responder rates versus placebo.
  • New unit Sequencio Therapeutics consolidated in-house cancer vaccine R&D; preclinical TROP2 vaccine candidates delivered complete tumor growth inhibition in breast and colorectal cancer mouse studies.
  • Commercial businesses faced tariff-driven cost pressure; nutraceutical segment revenue declined 2%, agriculture-related revenue fell 2%.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CK Life Sciences International (Holdings) Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260417-12109781), on April 17, 2026, and is solely responsible for the information contained therein.